Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-02-14
2006-02-14
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S321000, C530S350000, C530S806000
Reexamination Certificate
active
06998385
ABSTRACT:
The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. Mixtures of ISATX247 isomers exhibit a combination of enhanced potency and reduced toxicity over the naturally occurring and presently known cyclosporins. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.
REFERENCES:
patent: 4108985 (1978-08-01), Rüegger et al.
patent: 4160452 (1979-07-01), Theeuwes
patent: 4210581 (1980-07-01), Rüegger et al.
patent: 4220641 (1980-09-01), Traber et al.
patent: 4256108 (1981-03-01), Theeuwes
patent: 4265874 (1981-05-01), Bonsen et al.
patent: 4288431 (1981-09-01), Traber et al.
patent: 4384996 (1983-05-01), Bollinger et al.
patent: 4396542 (1983-08-01), Wenger
patent: 4554351 (1985-11-01), Wenger
patent: 4771122 (1988-09-01), Seebach
patent: 4963683 (1990-10-01), Avery et al.
patent: 5239057 (1993-08-01), Wang et al.
patent: 5284826 (1994-02-01), Eberle
patent: 5525590 (1996-06-01), Bollinger et al.
patent: 0 034 567 (1984-11-01), None
patent: 0 296 122 (1988-12-01), None
patent: 0 532 187 (1993-03-01), None
patent: 0 056 782 (1994-08-01), None
patent: WO 86/02080 (1986-04-01), None
patent: WO 99/18120 (1999-04-01), None
patent: WO 01/21554 (2001-03-01), None
patent: WO 01/28518 (2001-04-01), None
Abel, MD, et al., “ISATX247: A Novel Calcineurin Inhibitor”,J. Heart Lung Transpl., vol. 20, No. 2, p. 161 (2001) Abstract.
Abel, MD, et al., “ISATX247: A Novel Calcineurin Inhibitor with Minimal Renal Toxicity”,Am. J. of Transpl., vol. 1 (Suppl. 1), Abstract No. 1192 (2001).
Abel, MD, et al., “Phase 1 Evaluation of a Novel Calcineurin Inhibitor ISATX247”,Am. J. of Transpl., vol. 1 (Supp. 1), Abstract No. 1319 (2001).
Abel, MD, et al., “Preclinical Efficacy of a Novel Calcineurin Inhibitor: ISATX247”,Am. J. of Transpl., vol. 1 (Supp. 1), Abstract No. 1191, (2001).
Adams, M.W., “d-Alpha Tocopheryl Polyethylene Glycol 1000 Succinate (Eastman Vitamin E TPSG) as an Emulsifier and Bioenhancer for Drugs and Lipophilic Compounds” Pamphlet by Eastman Chemical Co., (Oct. 1996).
Aspeslet, L., et al., “ISATX247: A Novel Calcineurin Inhibiotr”,Transpl. Proc., vol. 33, pp. 1048-1051.
Bennet, W.M., “The Nephrotoxicity of New and Old Immunosuppresive Drugs”,Renal Failure, vol. 20, pp. 687-690 (1998).
Bestmann, H.J., et al., “(Z)-5-Decenyl Accetate, A Sex Attractant for the Male Turnip Moth”,Agnew. Chem. Int. Ed. Engl., vol. 17, No. 10, pp. 768-769 (1978).
Biellmann, J.F., et al., “Allylic and Benzylic Carbanions Substituted by Heteroatoms”,Organic Reactions, vol. 27, p. 9 (1982).
Birsan, T., et al., “Ex Vivo Evaluation of the Immunosuppressive Effect of the Novel Caldineurin Inhibitor ISATX247 on Whole Blood Lymphocytes of Non-Human Primates”,Am. J. of Transpl., 1(Supp. 1), Abstract No. 1199 (2001).
Borok, Z., et al., “Effect of Glutathione Aerosol on Oxidant-Antioxidant Imbalance in Idiopathic Pulmonary Fibrosis”,The Lancet, vol. 338, pp. 215 and 697.
Carlsen, H.J., et al., “A Greatly Improved Procedure for Ruthenium Tetraoxide Catalyzed Oxidations of Organic Compounds”,J. Org. Chem.,, vol. 46, No. 19, pp. 3936-3938 (1981).
Chang, T., et al., “The Effect of Water-Soluble Vitamin E On Cyclosporine Pharmacokinetics in Healthy Volunteers”,Clin. Pharmacol. Ther., vol. 59, pp. 297-303 (1996).
Corey, E.J., et al., “Highly Reactive Equivalents of Allylidenetriphenylphosporanes For the Stereospecific Synthesis of 1,3-dienes bu Cis-Olefination of Hindered Aldehydes”,Tetrahedron Letters, vol. 26, No. 47, pp. 5747-5748 (1985).
Eberle, M.K., et al., “Synthesis of the Main Metabolite (OL-17) of Cyclosporin A”,J. Org. Chem., vol. 57, pp. 2689-2691 (1992).
Ehlinger, E., et al., “Silicon in Synthesis. 10. The (trimethylsily)allyl amion: A β-acyl anion Equivalent for the conversion of Aldehydes and Ketones into γ-Lactones”,J. Am. Chem. Soc., vol. 102, No. 15, pp. 5004-5011 (1980).
Fruman, D.S., et al., “Calcineurin Phosphatase Activity in T Lymphocytes Is Inhibited by FK 506 and Cyclosporin A”,Proc. Natl. Acad. Sci. USA, vol. 89, pp. 3686-3690 (1992).
Granelli-Piperno, A., et al., “Lymphokine and Nonlymphokine mRNA Levels in Stimulated Human T Cells: Kinetics, Mitogen Requirements, and Effects of Cyclosporin A”J. Exp. Med., vol. 163, p. 922-937 (1986).
Hanson, J.R., “Esters as Protecting Groups for Alcohols”,Protecting Groups in Organic SynthesisCh. 2, pp. 24-25 (1999).
Herbert, M.F., et al., “Bioavailability of cyclosporine with Concomitant Rifampin Administration is Markedly Less than Predicted by Hepatic Enzyme Induction”,Clin. Pharmacol. Ther., vol. 52, pp. 453-457 (1992).
Hoffman, R.W., et al., “Diastereoselective Addition of γ-Alkylthio-Allylboronates to to Aldehydes”,Tetrahedron Letters, vol. 21, pp. 4883-4886 (1980).
Hoffman, R.W., et al., “Stereoselective Synthesis of Alcohols. 8. Diastereoselective Synthesis of β-methylhomoallyl Alcohols via Crotylboronates”,J. Org. Chem., vol. 46, pp. 1309-1314 (1981).
Hofle, G., et al., “4-Dialkylaminopyridines as Highly Active Acylation Catalysts”,Agnew. Chem. Int. Ed. Engl., vol. 17, pp. 569-583 (1978).
Hurdrlik, P.F. et al., “Stereospecific Olefin-Forming Elimination Reactions of β-Hydroxyalkylsilanes”,J. Am. Chem., Soc., vol. 97, No. 6, pp. 1464-1468 (1975).
Ikeda, Y., et al., “Stereoselective Synthesis of (Z)- and (E)-1,3-alkadienes from Aldehydes Using Organotitanium and Lithium Reagents”,Tetrahedron, vol. 43, No. 4, pp. 723-730 (1987).
Kobel, et al., “Directed Biosynthesis of Cyclosporins”,EP. J. Applied Microbiology and Biotechnology, vol. 14, pp. 237-240 (1982).
Maksymowych, WP, et al., “Amelioration of Established Collagen-Induced Arthritis by ISATX247: a Novel Calcineurin Inhibitor”,J. of Rheum., 28(supp 63) Abstract.
Maksymowych, WP, et al., “Prevention and Treatment of Antigen-Induced Arthritis by ISATX247, A Novel Calcineurin Inhibitor”,J. of Rheum., vol. 28 (Supp. 63) (2001).
McMurry, J., “19.12 Nucleophilic Addition of Phosphorus Ylides: The Wittig Reaction”, inOrganic Chemistry, 5thEd., pp. 780-783 (2000).
Peterson, D., “A Carbonyl Olefination Reaction Using Silyl-Substituted Organometallic Compounds”,J. Org. Chem., pp. 780-784 (1967).
Ramachandran, P.V., et al., eds., “Intramolecular Allylboration Reactions”, inOrganoboranes for Syntheses, pp. 162-164 and 174.
Reetz, M.T.,Organotitanium Reagents in Organic Synthesis, pp. VII, 148-149, 162-168 (1986-Springer-verlag, Berlin).
Rich, D., et al., “Synthesis and Antimitogenic Activities of Four Analogues of Cyclosporin A Modified in the 1-Position”,J. Med. Chem., vol. 29, p. 978-984 (1986).
Roush, W.R., “Allyorganometallics”,Comp. Org. Synth., vol. 2, pp. 1-53.
Schreiber, S.F., et al., “The Mechanism of Action of Cyclosporin A and FK506”,Immunol. Today, vol. 13, pp. 136-142 (1992).
Shapiro, A.M.J., et al., “Prolonged Islet Allograft Survival Without Toxicity Using ISATX247: a Novel Calcineurin Inhibitor”,Am. J. of Transpl., vol. 1, (Supp. 1), Abstract No. 8
Foster Robert T.
Naicker Selvaraj A.
Yatscoff Randall W.
Fish & Richardson P.C.
Gupta Anish
Isotechnika Inc.
LandOfFree
Cyclosporine analogue mixtures and their use as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclosporine analogue mixtures and their use as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclosporine analogue mixtures and their use as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3683209